WARPTECHNEWS · LAB

Home AI Business Tech Archive

Storia: A PureTech startup banks $180M for a new IPF drug — Warptech Lab News

WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

Home
Archivio
Editor's Brief
Cerca
Il tuo account
Newsletter tech/AI

Informazioni legali

Privacy Policy
Termini di servizio
Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

Storia in 3 fonti

A PureTech startup banks $180M for a new IPF drug

Celea, backed by investors such as RA Capital and Leaps by Bayer, is making what it says is an improved version of Roche's Esbriet.

Raccontata da

biopharmadive.com

morningstar.com

Confronto fonti

3 prospettive sulla stessa storia

AI · summaries

biopharmadive.comStai leggendo1 mese fa

A PureTech startup banks $180M for a new IPF drug

Celea, backed by investors such as RA Capital and Leaps by Bayer, is making what it says is an improved version of Roche's Esbriet.

endpoints.news1 mese fa

IPF biotech Celea gets $180M to follow paths of PureTech's Karuna, Seaport

Celea has corralled $180 million to see if its twist on an approved medicine for idiopathic pulmonary fibrosis can beat the original Roche treatment.

Leggi questa versione → originale

Timeline cronologica

giovedì 2 luglio 2026·biopharmadive.com
A PureTech startup banks $180M for a new IPF drug
Celea, backed by investors such as RA Capital and Leaps by Bayer, is making what it says is an improved version of Roche's Esbriet.
giovedì 2 luglio 2026·morningstar.com
PureTech Founded Entity Celea Therapeutics Completes $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care…
PureTech Founded Entity Celea Therapeutics Completes $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis…

morningstar.com1 mese fa

PureTech Founded Entity Celea Therapeutics Completes $180 Million Financing to Advance Deupirfenidone as a…

PureTech Founded Entity Celea Therapeutics Completes $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF)

Leggi questa versione → originale

giovedì 2 luglio 2026·

morningstar.com

Celea Therapeutics Announces $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic…

Celea Therapeutics Announces $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF)

giovedì 2 luglio 2026·

endpoints.news

IPF biotech Celea gets $180M to follow paths of PureTech's Karuna, Seaport

Celea has corralled $180 million to see if its twist on an approved medicine for idiopathic pulmonary fibrosis can beat the original Roche treatment.